Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Total Liabilities (2016 - 2026)

Champions Oncology has reported Total Liabilities over the past 16 years, most recently at $24.1 million for Q1 2026.

  • Quarterly results put Total Liabilities at $24.1 million for Q1 2026, down 4.33% from a year ago — trailing twelve months through Jan 2026 was $24.1 million (down 4.33% YoY), and the annual figure for FY2025 was $28.6 million, up 1.92%.
  • Total Liabilities for Q1 2026 was $24.1 million at Champions Oncology, down from $25.9 million in the prior quarter.
  • Over the last five years, Total Liabilities for CSBR hit a ceiling of $29.7 million in Q2 2023 and a floor of $24.1 million in Q1 2026.
  • Median Total Liabilities over the past 5 years was $27.0 million (2025), compared with a mean of $26.8 million.
  • Biggest five-year swings in Total Liabilities: skyrocketed 41.77% in 2022 and later decreased 12.91% in 2024.
  • Champions Oncology's Total Liabilities stood at $27.2 million in 2022, then grew by 3.71% to $28.2 million in 2023, then dropped by 12.91% to $24.6 million in 2024, then grew by 5.59% to $25.9 million in 2025, then fell by 7.18% to $24.1 million in 2026.
  • The last three reported values for Total Liabilities were $24.1 million (Q1 2026), $25.9 million (Q4 2025), and $27.0 million (Q3 2025) per Business Quant data.